Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 4 | 2021 | 331 | 0.940 |
Why?
|
| Medical Oncology | 1 | 2024 | 66 | 0.830 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2020 | 38 | 0.640 |
Why?
|
| Papillomaviridae | 1 | 2020 | 59 | 0.630 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 49 | 0.630 |
Why?
|
| Communication | 2 | 2024 | 572 | 0.620 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 412 | 0.610 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 129 | 0.570 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.520 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 419 | 0.510 |
Why?
|
| Immunotherapy | 4 | 2021 | 255 | 0.470 |
Why?
|
| Telemedicine | 1 | 2020 | 326 | 0.460 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1101 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 448 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2021 | 6659 | 0.210 |
Why?
|
| Language | 1 | 2024 | 150 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2021 | 182 | 0.190 |
Why?
|
| Neoplasms | 2 | 2024 | 1364 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 345 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2024 | 422 | 0.170 |
Why?
|
| Humans | 10 | 2024 | 63449 | 0.170 |
Why?
|
| Eosinophils | 1 | 2020 | 48 | 0.170 |
Why?
|
| Videoconferencing | 1 | 2020 | 11 | 0.170 |
Why?
|
| Aged | 6 | 2021 | 14449 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 103 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 47 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 160 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 242 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2020 | 201 | 0.150 |
Why?
|
| Blood Platelets | 1 | 2020 | 102 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 166 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Neutrophils | 1 | 2020 | 377 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2021 | 59 | 0.130 |
Why?
|
| Incidence | 1 | 2020 | 1377 | 0.120 |
Why?
|
| Male | 6 | 2021 | 29893 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 672 | 0.120 |
Why?
|
| Female | 6 | 2021 | 32883 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 674 | 0.100 |
Why?
|
| Hospitalization | 1 | 2020 | 1364 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 509 | 0.080 |
Why?
|
| Survival Rate | 2 | 2021 | 851 | 0.070 |
Why?
|
| Middle Aged | 2 | 2021 | 17615 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1749 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2020 | 99 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 6 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 132 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 5680 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 200 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 144 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 583 | 0.040 |
Why?
|
| Pneumonia | 1 | 2021 | 291 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 507 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2079 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3768 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 5463 | 0.020 |
Why?
|